Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)

In current clinical guidelines, such as those provided by the National Comprehensive Cancer Network (NCCN), evidence for treatment is based on a small clinical trial that included patients with HLRCC. They support the use of the combination of erlotinib and bevacizumab as the first therapeutic optio...

Descripción completa

Detalles Bibliográficos
Autores principales: Gurruchaga Sotés, Ibon, Alves, Ana Nuño, Arregui, Sandra Vicente, Santander Lobera, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293224/
https://www.ncbi.nlm.nih.gov/pubmed/34202275
http://dx.doi.org/10.3390/curroncol28040216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293224/
https://www.ncbi.nlm.nih.gov/pubmed/34202275
http://dx.doi.org/10.3390/curroncol28040216

Ejemplares similares